4D pharma plc

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, VRTX has a market cap of 114.83B. Regarding current trading prices, LBPSW is priced at $0.04, while VRTX trades at $447.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is -117.06. In terms of profitability, LBPSW's ROE is N/A, compared to VRTX's ROE of -0.06%. Regarding short-term risk, LBPSW is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, REGN has a market cap of 65.26B. Regarding current trading prices, LBPSW is priced at $0.04, while REGN trades at $614.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 15.63. In terms of profitability, LBPSW's ROE is N/A, compared to REGN's ROE of +0.15%. Regarding short-term risk, LBPSW is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, SGEN has a market cap of 43.15B. Regarding current trading prices, LBPSW is priced at $0.04, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, LBPSW's ROE is N/A, compared to SGEN's ROE of -0.17%. Regarding short-term risk, LBPSW is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ALNY has a market cap of 38.03B. Regarding current trading prices, LBPSW is priced at $0.04, while ALNY trades at $291.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is -138.24. In terms of profitability, LBPSW's ROE is N/A, compared to ALNY's ROE of -5.09%. Regarding short-term risk, LBPSW is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ARGX has a market cap of 35.31B. Regarding current trading prices, LBPSW is priced at $0.04, while ARGX trades at $578.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 35.26. In terms of profitability, LBPSW's ROE is N/A, compared to ARGX's ROE of +0.16%. Regarding short-term risk, LBPSW is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, BNTX has a market cap of 24.45B. Regarding current trading prices, LBPSW is priced at $0.04, while BNTX trades at $101.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -28.57. In terms of profitability, LBPSW's ROE is N/A, compared to BNTX's ROE of -0.04%. Regarding short-term risk, LBPSW is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, BGNE has a market cap of 20.21B. Regarding current trading prices, LBPSW is priced at $0.04, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, LBPSW's ROE is N/A, compared to BGNE's ROE of -0.12%. Regarding short-term risk, LBPSW is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, DNA-WT has a market cap of 18.73B. Regarding current trading prices, LBPSW is priced at $0.04, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, LBPSW's ROE is N/A, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, LBPSW is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, RPRX has a market cap of 18.63B. Regarding current trading prices, LBPSW is priced at $0.04, while RPRX trades at $33.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 13.51. In terms of profitability, LBPSW's ROE is N/A, compared to RPRX's ROE of +0.16%. Regarding short-term risk, LBPSW is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, SMMT has a market cap of 17.99B. Regarding current trading prices, LBPSW is priced at $0.04, while SMMT trades at $24.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -71.74. In terms of profitability, LBPSW's ROE is N/A, compared to SMMT's ROE of -0.70%. Regarding short-term risk, LBPSW is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, UTHR has a market cap of 13.96B. Regarding current trading prices, LBPSW is priced at $0.04, while UTHR trades at $309.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 12.33. In terms of profitability, LBPSW's ROE is N/A, compared to UTHR's ROE of +0.19%. Regarding short-term risk, LBPSW is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, INCY has a market cap of 12.64B. Regarding current trading prices, LBPSW is priced at $0.04, while INCY trades at $65.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 326.50. In terms of profitability, LBPSW's ROE is N/A, compared to INCY's ROE of +0.01%. Regarding short-term risk, LBPSW is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, GMAB has a market cap of 12.60B. Regarding current trading prices, LBPSW is priced at $0.04, while GMAB trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 11.96. In terms of profitability, LBPSW's ROE is N/A, compared to GMAB's ROE of +0.26%. Regarding short-term risk, LBPSW is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, KRTX has a market cap of 12.60B. Regarding current trading prices, LBPSW is priced at $0.04, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, LBPSW's ROE is N/A, compared to KRTX's ROE of -0.25%. Regarding short-term risk, LBPSW is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, EXEL has a market cap of 12.10B. Regarding current trading prices, LBPSW is priced at $0.04, while EXEL trades at $44.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 20.26. In terms of profitability, LBPSW's ROE is N/A, compared to EXEL's ROE of +0.29%. Regarding short-term risk, LBPSW is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, BMRN has a market cap of 11.49B. Regarding current trading prices, LBPSW is priced at $0.04, while BMRN trades at $59.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 22.20. In terms of profitability, LBPSW's ROE is N/A, compared to BMRN's ROE of +0.09%. Regarding short-term risk, LBPSW is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, MRNA has a market cap of 10.82B. Regarding current trading prices, LBPSW is priced at $0.04, while MRNA trades at $27.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -3.21. In terms of profitability, LBPSW's ROE is N/A, compared to MRNA's ROE of -0.30%. Regarding short-term risk, LBPSW is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ASND has a market cap of 9.75B. Regarding current trading prices, LBPSW is priced at $0.04, while ASND trades at $161.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -24.90. In terms of profitability, LBPSW's ROE is N/A, compared to ASND's ROE of +1.91%. Regarding short-term risk, LBPSW is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, RXDX has a market cap of 9.56B. Regarding current trading prices, LBPSW is priced at $0.04, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, LBPSW's ROE is N/A, compared to RXDX's ROE of -0.31%. Regarding short-term risk, LBPSW is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, IMGN has a market cap of 8.73B. Regarding current trading prices, LBPSW is priced at $0.04, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, LBPSW's ROE is N/A, compared to IMGN's ROE of +0.05%. Regarding short-term risk, LBPSW is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, CERE has a market cap of 8.19B. Regarding current trading prices, LBPSW is priced at $0.04, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, LBPSW's ROE is N/A, compared to CERE's ROE of -0.99%. Regarding short-term risk, LBPSW is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, CORT has a market cap of 8.08B. Regarding current trading prices, LBPSW is priced at $0.04, while CORT trades at $76.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 66.30. In terms of profitability, LBPSW's ROE is N/A, compared to CORT's ROE of +0.20%. Regarding short-term risk, LBPSW is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ROIV has a market cap of 7.88B. Regarding current trading prices, LBPSW is priced at $0.04, while ROIV trades at $11.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -11.04. In terms of profitability, LBPSW's ROE is N/A, compared to ROIV's ROE of -0.02%. Regarding short-term risk, LBPSW is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ROIVW has a market cap of 7.83B. Regarding current trading prices, LBPSW is priced at $0.04, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, LBPSW's ROE is N/A, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, LBPSW is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, TECH has a market cap of 7.76B. Regarding current trading prices, LBPSW is priced at $0.04, while TECH trades at $49.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 59.67. In terms of profitability, LBPSW's ROE is N/A, compared to TECH's ROE of +0.06%. Regarding short-term risk, LBPSW is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, RVMD has a market cap of 7.54B. Regarding current trading prices, LBPSW is priced at $0.04, while RVMD trades at $40.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -10.09. In terms of profitability, LBPSW's ROE is N/A, compared to RVMD's ROE of -0.37%. Regarding short-term risk, LBPSW is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, JAZZ has a market cap of 6.84B. Regarding current trading prices, LBPSW is priced at $0.04, while JAZZ trades at $111.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 15.08. In terms of profitability, LBPSW's ROE is N/A, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, LBPSW is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, BPMC has a market cap of 6.65B. Regarding current trading prices, LBPSW is priced at $0.04, while BPMC trades at $103.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -41.04. In terms of profitability, LBPSW's ROE is N/A, compared to BPMC's ROE of -0.49%. Regarding short-term risk, LBPSW is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, HALO has a market cap of 6.59B. Regarding current trading prices, LBPSW is priced at $0.04, while HALO trades at $53.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 14.22. In terms of profitability, LBPSW's ROE is N/A, compared to HALO's ROE of +1.22%. Regarding short-term risk, LBPSW is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, RETA has a market cap of 6.57B. Regarding current trading prices, LBPSW is priced at $0.04, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, LBPSW's ROE is N/A, compared to RETA's ROE of +0.47%. Regarding short-term risk, LBPSW is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, MDGL has a market cap of 6.50B. Regarding current trading prices, LBPSW is priced at $0.04, while MDGL trades at $292.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -16.41. In terms of profitability, LBPSW's ROE is N/A, compared to MDGL's ROE of -0.51%. Regarding short-term risk, LBPSW is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, BBIO has a market cap of 6.40B. Regarding current trading prices, LBPSW is priced at $0.04, while BBIO trades at $33.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -9.47. In terms of profitability, LBPSW's ROE is N/A, compared to BBIO's ROE of +0.49%. Regarding short-term risk, LBPSW is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, VRNA has a market cap of 6.35B. Regarding current trading prices, LBPSW is priced at $0.04, while VRNA trades at $74.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -37.36. In terms of profitability, LBPSW's ROE is N/A, compared to VRNA's ROE of -0.90%. Regarding short-term risk, LBPSW is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, TGTX has a market cap of 5.63B. Regarding current trading prices, LBPSW is priced at $0.04, while TGTX trades at $35.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 141.88. In terms of profitability, LBPSW's ROE is N/A, compared to TGTX's ROE of +0.19%. Regarding short-term risk, LBPSW is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ABCM has a market cap of 5.52B. Regarding current trading prices, LBPSW is priced at $0.04, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, LBPSW's ROE is N/A, compared to ABCM's ROE of -0.01%. Regarding short-term risk, LBPSW is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ISEE has a market cap of 5.51B. Regarding current trading prices, LBPSW is priced at $0.04, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, LBPSW's ROE is N/A, compared to ISEE's ROE of -0.39%. Regarding short-term risk, LBPSW is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, TLX has a market cap of 5.49B. Regarding current trading prices, LBPSW is priced at $0.04, while TLX trades at $16.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas TLX's P/E ratio is 182.22. In terms of profitability, LBPSW's ROE is N/A, compared to TLX's ROE of +0.14%. Regarding short-term risk, LBPSW is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, IONS has a market cap of 5.49B. Regarding current trading prices, LBPSW is priced at $0.04, while IONS trades at $34.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -11.53. In terms of profitability, LBPSW's ROE is N/A, compared to IONS's ROE of -0.00%. Regarding short-term risk, LBPSW is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, NUVL has a market cap of 5.45B. Regarding current trading prices, LBPSW is priced at $0.04, while NUVL trades at $75.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -17.17. In terms of profitability, LBPSW's ROE is N/A, compared to NUVL's ROE of -0.31%. Regarding short-term risk, LBPSW is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, AXSM has a market cap of 5.33B. Regarding current trading prices, LBPSW is priced at $0.04, while AXSM trades at $108.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -18.78. In terms of profitability, LBPSW's ROE is N/A, compared to AXSM's ROE of -3.64%. Regarding short-term risk, LBPSW is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ALKS has a market cap of 5.22B. Regarding current trading prices, LBPSW is priced at $0.04, while ALKS trades at $31.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 15.09. In terms of profitability, LBPSW's ROE is N/A, compared to ALKS's ROE of +0.25%. Regarding short-term risk, LBPSW is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ADMA has a market cap of 4.88B. Regarding current trading prices, LBPSW is priced at $0.04, while ADMA trades at $20.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ADMA's P/E ratio is 24.33. In terms of profitability, LBPSW's ROE is N/A, compared to ADMA's ROE of +0.72%. Regarding short-term risk, LBPSW is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, PCVX has a market cap of 4.72B. Regarding current trading prices, LBPSW is priced at $0.04, while PCVX trades at $36.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -9.17. In terms of profitability, LBPSW's ROE is N/A, compared to PCVX's ROE of -0.17%. Regarding short-term risk, LBPSW is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ALPN has a market cap of 4.46B. Regarding current trading prices, LBPSW is priced at $0.04, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, LBPSW's ROE is N/A, compared to ALPN's ROE of -0.15%. Regarding short-term risk, LBPSW is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, OPT has a market cap of 4.20B. Regarding current trading prices, LBPSW is priced at $0.04, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, LBPSW's ROE is N/A, compared to OPT's ROE of +2.60%. Regarding short-term risk, LBPSW is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, MRTX has a market cap of 4.12B. Regarding current trading prices, LBPSW is priced at $0.04, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, LBPSW's ROE is N/A, compared to MRTX's ROE of -0.40%. Regarding short-term risk, LBPSW is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, RYTM has a market cap of 4.06B. Regarding current trading prices, LBPSW is priced at $0.04, while RYTM trades at $63.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -22.81. In terms of profitability, LBPSW's ROE is N/A, compared to RYTM's ROE of -1.80%. Regarding short-term risk, LBPSW is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, SRPT has a market cap of 3.93B. Regarding current trading prices, LBPSW is priced at $0.04, while SRPT trades at $39.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas SRPT's P/E ratio is -15.15. In terms of profitability, LBPSW's ROE is N/A, compared to SRPT's ROE of -0.20%. Regarding short-term risk, LBPSW is more volatile compared to SRPT. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, CYTK has a market cap of 3.90B. Regarding current trading prices, LBPSW is priced at $0.04, while CYTK trades at $32.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -6.17. In terms of profitability, LBPSW's ROE is N/A, compared to CYTK's ROE of +8.01%. Regarding short-term risk, LBPSW is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, RNA has a market cap of 3.81B. Regarding current trading prices, LBPSW is priced at $0.04, while RNA trades at $31.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas RNA's P/E ratio is -10.55. In terms of profitability, LBPSW's ROE is N/A, compared to RNA's ROE of -0.27%. Regarding short-term risk, LBPSW is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, KRYS has a market cap of 3.80B. Regarding current trading prices, LBPSW is priced at $0.04, while KRYS trades at $131.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 31.55. In terms of profitability, LBPSW's ROE is N/A, compared to KRYS's ROE of +0.14%. Regarding short-term risk, LBPSW is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, AKRO has a market cap of 3.79B. Regarding current trading prices, LBPSW is priced at $0.04, while AKRO trades at $47.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -12.69. In terms of profitability, LBPSW's ROE is N/A, compared to AKRO's ROE of -0.32%. Regarding short-term risk, LBPSW is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, RYZB has a market cap of 3.75B. Regarding current trading prices, LBPSW is priced at $0.04, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, LBPSW's ROE is N/A, compared to RYZB's ROE of +0.83%. Regarding short-term risk, LBPSW is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, PTCT has a market cap of 3.74B. Regarding current trading prices, LBPSW is priced at $0.04, while PTCT trades at $47.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 7.25. In terms of profitability, LBPSW's ROE is N/A, compared to PTCT's ROE of -0.72%. Regarding short-term risk, LBPSW is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, CBAY has a market cap of 3.73B. Regarding current trading prices, LBPSW is priced at $0.04, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, LBPSW's ROE is N/A, compared to CBAY's ROE of -0.32%. Regarding short-term risk, LBPSW is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ACAD has a market cap of 3.63B. Regarding current trading prices, LBPSW is priced at $0.04, while ACAD trades at $21.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 15.83. In terms of profitability, LBPSW's ROE is N/A, compared to ACAD's ROE of +0.35%. Regarding short-term risk, LBPSW is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, RARE has a market cap of 3.53B. Regarding current trading prices, LBPSW is priced at $0.04, while RARE trades at $37.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas RARE's P/E ratio is -6.41. In terms of profitability, LBPSW's ROE is N/A, compared to RARE's ROE of -1.86%. Regarding short-term risk, LBPSW is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, SWTX has a market cap of 3.49B. Regarding current trading prices, LBPSW is priced at $0.04, while SWTX trades at $46.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.58. In terms of profitability, LBPSW's ROE is N/A, compared to SWTX's ROE of -0.51%. Regarding short-term risk, LBPSW is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, CRSP has a market cap of 3.39B. Regarding current trading prices, LBPSW is priced at $0.04, while CRSP trades at $39.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -8.75. In terms of profitability, LBPSW's ROE is N/A, compared to CRSP's ROE of -0.20%. Regarding short-term risk, LBPSW is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ACLX has a market cap of 3.34B. Regarding current trading prices, LBPSW is priced at $0.04, while ACLX trades at $60.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -20.25. In terms of profitability, LBPSW's ROE is N/A, compared to ACLX's ROE of -0.35%. Regarding short-term risk, LBPSW is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, VKTX has a market cap of 3.22B. Regarding current trading prices, LBPSW is priced at $0.04, while VKTX trades at $28.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -24.72. In terms of profitability, LBPSW's ROE is N/A, compared to VKTX's ROE of -0.14%. Regarding short-term risk, LBPSW is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, SLNO has a market cap of 3.21B. Regarding current trading prices, LBPSW is priced at $0.04, while SLNO trades at $69.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas SLNO's P/E ratio is -15.97. In terms of profitability, LBPSW's ROE is N/A, compared to SLNO's ROE of -0.78%. Regarding short-term risk, LBPSW is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, MTSR has a market cap of 3.07B. Regarding current trading prices, LBPSW is priced at $0.04, while MTSR trades at $29.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -11.56. In terms of profitability, LBPSW's ROE is N/A, compared to MTSR's ROE of -0.63%. Regarding short-term risk, LBPSW is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, MRUS has a market cap of 3.05B. Regarding current trading prices, LBPSW is priced at $0.04, while MRUS trades at $44.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -10.58. In terms of profitability, LBPSW's ROE is N/A, compared to MRUS's ROE of -0.41%. Regarding short-term risk, LBPSW is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, CPRX has a market cap of 3.01B. Regarding current trading prices, LBPSW is priced at $0.04, while CPRX trades at $24.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 15.72. In terms of profitability, LBPSW's ROE is N/A, compared to CPRX's ROE of +0.28%. Regarding short-term risk, LBPSW is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, SRRK has a market cap of 2.99B. Regarding current trading prices, LBPSW is priced at $0.04, while SRRK trades at $31.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -12.37. In terms of profitability, LBPSW's ROE is N/A, compared to SRRK's ROE of -1.18%. Regarding short-term risk, LBPSW is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, CRNX has a market cap of 2.94B. Regarding current trading prices, LBPSW is priced at $0.04, while CRNX trades at $31.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -8.26. In terms of profitability, LBPSW's ROE is N/A, compared to CRNX's ROE of -0.31%. Regarding short-term risk, LBPSW is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, PTGX has a market cap of 2.89B. Regarding current trading prices, LBPSW is priced at $0.04, while PTGX trades at $46.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is 59.76. In terms of profitability, LBPSW's ROE is N/A, compared to PTGX's ROE of +0.09%. Regarding short-term risk, LBPSW is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, MORF has a market cap of 2.86B. Regarding current trading prices, LBPSW is priced at $0.04, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas MORF's P/E ratio is -14.88. In terms of profitability, LBPSW's ROE is N/A, compared to MORF's ROE of -0.27%. Regarding short-term risk, LBPSW is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, MOR has a market cap of 2.86B. Regarding current trading prices, LBPSW is priced at $0.04, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas MOR's P/E ratio is -12.64. In terms of profitability, LBPSW's ROE is N/A, compared to MOR's ROE of +7.43%. Regarding short-term risk, LBPSW is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, LEGN has a market cap of 2.77B. Regarding current trading prices, LBPSW is priced at $0.04, while LEGN trades at $30.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -25.48. In terms of profitability, LBPSW's ROE is N/A, compared to LEGN's ROE of -0.20%. Regarding short-term risk, LBPSW is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, KDNY has a market cap of 2.71B. Regarding current trading prices, LBPSW is priced at $0.04, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas KDNY's P/E ratio is -12.47. In terms of profitability, LBPSW's ROE is N/A, compared to KDNY's ROE of -0.41%. Regarding short-term risk, LBPSW is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, MYOV has a market cap of 2.62B. Regarding current trading prices, LBPSW is priced at $0.04, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas MYOV's P/E ratio is -14.05. In terms of profitability, LBPSW's ROE is N/A, compared to MYOV's ROE of +0.50%. Regarding short-term risk, LBPSW is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, IBRX has a market cap of 2.56B. Regarding current trading prices, LBPSW is priced at $0.04, while IBRX trades at $2.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -5.09. In terms of profitability, LBPSW's ROE is N/A, compared to IBRX's ROE of +0.65%. Regarding short-term risk, LBPSW is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, MLTX has a market cap of 2.56B. Regarding current trading prices, LBPSW is priced at $0.04, while MLTX trades at $40.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas MLTX's P/E ratio is -17.51. In terms of profitability, LBPSW's ROE is N/A, compared to MLTX's ROE of -0.00%. Regarding short-term risk, LBPSW is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, IMVT has a market cap of 2.55B. Regarding current trading prices, LBPSW is priced at $0.04, while IMVT trades at $15.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -5.73. In terms of profitability, LBPSW's ROE is N/A, compared to IMVT's ROE of -0.78%. Regarding short-term risk, LBPSW is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, XENE has a market cap of 2.41B. Regarding current trading prices, LBPSW is priced at $0.04, while XENE trades at $31.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -9.76. In terms of profitability, LBPSW's ROE is N/A, compared to XENE's ROE of -0.32%. Regarding short-term risk, LBPSW is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, APGE has a market cap of 2.40B. Regarding current trading prices, LBPSW is priced at $0.04, while APGE trades at $40.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -11.17. In terms of profitability, LBPSW's ROE is N/A, compared to APGE's ROE of -0.19%. Regarding short-term risk, LBPSW is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, PRVB has a market cap of 2.38B. Regarding current trading prices, LBPSW is priced at $0.04, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas PRVB's P/E ratio is -16.43. In terms of profitability, LBPSW's ROE is N/A, compared to PRVB's ROE of +1.33%. Regarding short-term risk, LBPSW is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, LBPH has a market cap of 2.34B. Regarding current trading prices, LBPSW is priced at $0.04, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas LBPH's P/E ratio is -26.66. In terms of profitability, LBPSW's ROE is N/A, compared to LBPH's ROE of -0.33%. Regarding short-term risk, LBPSW is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, APLS has a market cap of 2.33B. Regarding current trading prices, LBPSW is priced at $0.04, while APLS trades at $18.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas APLS's P/E ratio is -10.28. In terms of profitability, LBPSW's ROE is N/A, compared to APLS's ROE of -1.00%. Regarding short-term risk, LBPSW is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, DICE has a market cap of 2.27B. Regarding current trading prices, LBPSW is priced at $0.04, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas DICE's P/E ratio is -21.91. In terms of profitability, LBPSW's ROE is N/A, compared to DICE's ROE of +0.56%. Regarding short-term risk, LBPSW is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, VCYT has a market cap of 2.26B. Regarding current trading prices, LBPSW is priced at $0.04, while VCYT trades at $28.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas VCYT's P/E ratio is 68.60. In terms of profitability, LBPSW's ROE is N/A, compared to VCYT's ROE of +0.03%. Regarding short-term risk, LBPSW is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, ARWR has a market cap of 2.25B. Regarding current trading prices, LBPSW is priced at $0.04, while ARWR trades at $16.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -13.14. In terms of profitability, LBPSW's ROE is N/A, compared to ARWR's ROE of -0.46%. Regarding short-term risk, LBPSW is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, MIRM has a market cap of 2.25B. Regarding current trading prices, LBPSW is priced at $0.04, while MIRM trades at $45.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -28.16. In terms of profitability, LBPSW's ROE is N/A, compared to MIRM's ROE of -0.34%. Regarding short-term risk, LBPSW is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, VCEL has a market cap of 2.19B. Regarding current trading prices, LBPSW is priced at $0.04, while VCEL trades at $43.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas VCEL's P/E ratio is 870.40. In terms of profitability, LBPSW's ROE is N/A, compared to VCEL's ROE of +0.01%. Regarding short-term risk, LBPSW is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, NAMS has a market cap of 2.17B. Regarding current trading prices, LBPSW is priced at $0.04, while NAMS trades at $19.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -10.52. In terms of profitability, LBPSW's ROE is N/A, compared to NAMS's ROE of -0.26%. Regarding short-term risk, LBPSW is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, BCRX has a market cap of 2.16B. Regarding current trading prices, LBPSW is priced at $0.04, while BCRX trades at $10.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas BCRX's P/E ratio is -39.73. In terms of profitability, LBPSW's ROE is N/A, compared to BCRX's ROE of +0.15%. Regarding short-term risk, LBPSW is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, NAMSW has a market cap of 2.15B. Regarding current trading prices, LBPSW is priced at $0.04, while NAMSW trades at $8.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas NAMSW's P/E ratio is N/A. In terms of profitability, LBPSW's ROE is N/A, compared to NAMSW's ROE of -0.26%. Regarding short-term risk, LBPSW is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, CALT has a market cap of 2.15B. Regarding current trading prices, LBPSW is priced at $0.04, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas CALT's P/E ratio is -22.73. In terms of profitability, LBPSW's ROE is N/A, compared to CALT's ROE of -2.10%. Regarding short-term risk, LBPSW is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, BLTE has a market cap of 2.13B. Regarding current trading prices, LBPSW is priced at $0.04, while BLTE trades at $65.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -48.10. In terms of profitability, LBPSW's ROE is N/A, compared to BLTE's ROE of -0.31%. Regarding short-term risk, LBPSW is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, DNLI has a market cap of 2.08B. Regarding current trading prices, LBPSW is priced at $0.04, while DNLI trades at $14.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -5.35. In terms of profitability, LBPSW's ROE is N/A, compared to DNLI's ROE of -0.36%. Regarding short-term risk, LBPSW is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, KYMR has a market cap of 2.05B. Regarding current trading prices, LBPSW is priced at $0.04, while KYMR trades at $31.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -10.11. In terms of profitability, LBPSW's ROE is N/A, compared to KYMR's ROE of -0.30%. Regarding short-term risk, LBPSW is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, HRMY has a market cap of 2.05B. Regarding current trading prices, LBPSW is priced at $0.04, while HRMY trades at $35.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas HRMY's P/E ratio is 13.60. In terms of profitability, LBPSW's ROE is N/A, compared to HRMY's ROE of +0.24%. Regarding short-term risk, LBPSW is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, FOLD has a market cap of 2.03B. Regarding current trading prices, LBPSW is priced at $0.04, while FOLD trades at $6.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -73.22. In terms of profitability, LBPSW's ROE is N/A, compared to FOLD's ROE of -0.17%. Regarding short-term risk, LBPSW is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, CGON has a market cap of 2.02B. Regarding current trading prices, LBPSW is priced at $0.04, while CGON trades at $26.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -17.71. In terms of profitability, LBPSW's ROE is N/A, compared to CGON's ROE of -0.11%. Regarding short-term risk, LBPSW is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, LGND has a market cap of 2.02B. Regarding current trading prices, LBPSW is priced at $0.04, while LGND trades at $104.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas LGND's P/E ratio is -14.39. In terms of profitability, LBPSW's ROE is N/A, compared to LGND's ROE of -0.16%. Regarding short-term risk, LBPSW is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, AAPG has a market cap of 1.97B. Regarding current trading prices, LBPSW is priced at $0.04, while AAPG trades at $22.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas AAPG's P/E ratio is -30.73. In terms of profitability, LBPSW's ROE is N/A, compared to AAPG's ROE of -2.50%. Regarding short-term risk, LBPSW is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.

LBPSW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LBPSW stands at N/A. In comparison, KNSA has a market cap of 1.95B. Regarding current trading prices, LBPSW is priced at $0.04, while KNSA trades at $26.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LBPSW currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is -111.25. In terms of profitability, LBPSW's ROE is N/A, compared to KNSA's ROE of -0.04%. Regarding short-term risk, LBPSW is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for LBPSW.